{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:04:52Z","timestamp":1793736292809,"version":"4.6.1"},"reference-count":130,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clnu.2023.10.004","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:33:44Z","timestamp":1696538024000},"page":"2338-2352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A\u00a0controversy that must be solved"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1369-3657","authenticated-orcid":false,"given":"Baris","family":"Afsar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rengin Elsurer","family":"Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2023.10.004_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.2337\/dc06-2537","article-title":"Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study","volume":"30","author":"Park","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2023.10.004_bib2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2337\/dc09-2310","article-title":"Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS)","volume":"33","author":"Kim","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2023.10.004_bib3","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124952","article-title":"Hyperglycemia induces skeletal muscle atrophy via a WWP1\/KLF15 axis","volume":"4","author":"Hirata","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clnu.2023.10.004_bib4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00592-016-0880-y","article-title":"Muscle dysfunction in type 2 diabetes: a major threat to patient's mobility and independence","volume":"53","author":"Bianchi","year":"2016","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clnu.2023.10.004_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/jdi.13436","article-title":"High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: findings from the Impact of Diabetes Mellitus on Dynapenia study","volume":"12","author":"Mori","year":"2021","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.clnu.2023.10.004_bib6","first-page":"393","article-title":"Sarcopenia - definition, radiological diagnosis, clinical significance","volume":"195","author":"Vogele","year":"2023","journal-title":"R\u00f6fo"},{"key":"10.1016\/j.clnu.2023.10.004_bib7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.clnu.2014.03.007","article-title":"Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia","volume":"33","author":"Biolo","year":"2014","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clnu.2023.10.004_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI88880","article-title":"Skeletal muscle inflammation and insulin resistance in obesity","volume":"127","author":"Wu","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"Suppl 2","key":"10.1016\/j.clnu.2023.10.004_bib9","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.2337\/dc09-S302","article-title":"Skeletal muscle insulin resistance is the primary defect in type 2 diabetes","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2023.10.004_bib10","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1210\/jc.2012-1444","article-title":"Metabolic slowing with massive weight loss despite preservation of fat-free mass","volume":"97","author":"Johannsen","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clnu.2023.10.004_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.clnu.2023.10.004_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s43440-022-00442-4","article-title":"Sodium-glucose cotransporter inhibitors and kidney fibrosis: review of the current evidence and related mechanisms","volume":"75","author":"Afsar","year":"2023","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.clnu.2023.10.004_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clnu.2023.10.004_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clnu.2023.10.004_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7861\/clinmedicine.16-5-455","article-title":"Sarcopenia and frailty: new challenges for clinical practice","volume":"16","author":"Dodds","year":"2016","journal-title":"Clin Med"},{"key":"10.1016\/j.clnu.2023.10.004_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/nu12010211","article-title":"Sarcopenia and heart failure","volume":"12","author":"Curcio","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2023.10.004_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FJC.0000000000001380","article-title":"Mechanisms of SGLT2 inhibitors in heart failure and their clinical value","volume":"81","author":"Xie","year":"2023","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.clnu.2023.10.004_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2016.11.028","article-title":"Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice","volume":"794","author":"Naznin","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clnu.2023.10.004_bib19","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2337\/db16-1410","article-title":"Correcting postprandial hyperglycemia in zucker diabetic fatty rats with an SGLT2 inhibitor restores glucose effectiveness in the liver and reduces insulin resistance in skeletal muscle","volume":"66","author":"O'Brien","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.clnu.2023.10.004_bib20","doi-asserted-by":"crossref","first-page":"E492","DOI":"10.1152\/ajpendo.00401.2019","article-title":"Combined effect of canagliflozin and exercise training on high-fat diet-fed mice","volume":"318","author":"Tanaka","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clnu.2023.10.004_bib21","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/dom.14508","article-title":"Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes","volume":"23","author":"Matsuba","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2023.10.004_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/db21-0934","article-title":"Canagliflozin prevents hyperglycemia-associated muscle extracellular matrix accumulation and improves the adaptive response to aerobic exercise","volume":"71","author":"MacDonald","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.clnu.2023.10.004_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/BCJ20210700","article-title":"Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice","volume":"479","author":"Otsuka","year":"2022","journal-title":"Biochem J"},{"key":"10.1016\/j.clnu.2023.10.004_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.curtheres.2017.07.002","article-title":"Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study","volume":"87","author":"Tobita","year":"2017","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.clnu.2023.10.004_bib25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J\u00a0Atherosclerosis Thromb"},{"key":"10.1016\/j.clnu.2023.10.004_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2023.10.004_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/jdi.13179","article-title":"Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial","volume":"11","author":"Yamakage","year":"2020","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.clnu.2023.10.004_bib28","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","article-title":"Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients - a randomized controlled trial","volume":"84","author":"Kayano","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.clnu.2023.10.004_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1507\/endocrj.EJ20-0599","article-title":"Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial","volume":"68","author":"Bouchi","year":"2021","journal-title":"Endocr J"},{"key":"10.1016\/j.clnu.2023.10.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109781","article-title":"Metabolic changes induced by dapagliflozin, an SGLT2 inhibitor, in Japanese\u00a0patients with type 2 diabetes treated by oral anti-diabetic agents: a randomized, clinical trial","volume":"186","author":"Horibe","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clnu.2023.10.004_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172810","article-title":"Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure","volume":"866","author":"Nambu","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clnu.2023.10.004_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1530\/EC-20-0082","article-title":"Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use","volume":"9","author":"Goto","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.clnu.2023.10.004_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-21486-9","article-title":"Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin","volume":"12","author":"Zeng","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2023.10.004_bib34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1507\/endocrj.EJ15-0749","article-title":"Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy","volume":"63","author":"Yamamoto","year":"2016","journal-title":"Endocr J"},{"key":"10.1016\/j.clnu.2023.10.004_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13340-017-0307-1","article-title":"Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin","volume":"8","author":"Kato","year":"2017","journal-title":"Diabetol Int"},{"key":"10.1016\/j.clnu.2023.10.004_bib36","first-page":"586","article-title":"Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus","volume":"9","author":"Kawata","year":"2017","journal-title":"J\u00a0Clin Med Res"},{"key":"10.1016\/j.clnu.2023.10.004_bib37","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/14656566.2017.1363888","article-title":"Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes","volume":"18","author":"Ohta","year":"2017","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.clnu.2023.10.004_bib38","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1515\/med-2018-0059","article-title":"Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease","volume":"13","author":"Miyake","year":"2018","journal-title":"Open Med"},{"key":"10.1016\/j.clnu.2023.10.004_bib39","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/dom.13421","article-title":"Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study","volume":"20","author":"Tsurutani","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2023.10.004_bib40","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jdi.12985","article-title":"Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial","volume":"10","author":"Inoue","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.clnu.2023.10.004_bib41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/jdi.13340","article-title":"Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: subanalysis of a prospective, randomized, controlled study (PRIME-V study)","volume":"12","author":"Koshizaka","year":"2021","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.clnu.2023.10.004_bib42","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s13300-021-01047-5","article-title":"Effects of sodium glucose Co-transporter 2 inhibitors in type 1 diabetes mellitus on body composition and glucose variabilities: single-arm, exploratory trial","volume":"12","author":"Baba","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clnu.2023.10.004_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","article-title":"Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study","volume":"16","author":"Bouchi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clnu.2023.10.004_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12851","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study","volume":"10","author":"Sasaki","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.clnu.2023.10.004_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3164\/jcbn.18-114","article-title":"The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db\/Db mice by suppressing the expression of foxo1","volume":"65","author":"Okamura","year":"2019","journal-title":"J\u00a0Clin Biochem Nutr"},{"key":"10.1016\/j.clnu.2023.10.004_bib46","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jcsm.12814","article-title":"Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db\/db mice","volume":"13","author":"Bamba","year":"2022","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2023.10.004_bib47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1507\/endocrj.EJ21-0696","article-title":"Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes","volume":"69","author":"Bando","year":"2022","journal-title":"Endocr J"},{"key":"10.1016\/j.clnu.2023.10.004_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/nu14173531","article-title":"Gut microbiota changes by an SGLT2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db\/db mice","volume":"14","author":"Hata","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2023.10.004_bib49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3164\/jcbn.22-58","article-title":"Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats","volume":"72","author":"Xie","year":"2023","journal-title":"J\u00a0Clin Biochem Nutr"},{"key":"10.1016\/j.clnu.2023.10.004_bib50","article-title":"Effect of tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus","volume":"2018","author":"Kamei","year":"2018","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.clnu.2023.10.004_bib51","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/dom.13211","article-title":"Tofogliflozin decreases body fat mass and improves peripheral insulin resistance","volume":"20","author":"Matsuba","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2023.10.004_bib52","first-page":"736","article-title":"Increased grip strength with sodium-glucose cotransporter 2","volume":"8","author":"Sano","year":"2016","journal-title":"J\u00a0Diabetes"},{"key":"10.1016\/j.clnu.2023.10.004_bib53","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/hepr.12834","article-title":"Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus","volume":"47","author":"Seko","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clnu.2023.10.004_bib54","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s13300-018-0447-8","article-title":"There is a close association between the recovery of liver injury and glycemic control after SGLT2 inhibitor treatment in Japanese subjects with type 2 diabetes: a retrospective clinical study","volume":"9","author":"Kinoshita","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clnu.2023.10.004_bib55","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40261-019-00785-6","article-title":"Effect of sodium glucose Co-transporter 2 inhibitors on liver fat mass and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"39","author":"Arase","year":"2019","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clnu.2023.10.004_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13340-021-00512-7","article-title":"Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes","volume":"13","author":"Sakamoto","year":"2022","journal-title":"Diabetol Int"},{"key":"10.1016\/j.clnu.2023.10.004_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113679","article-title":"Unfavorable effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the skeletal system of nondiabetic rats","volume":"155","author":"Londzin","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clnu.2023.10.004_bib58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3803\/EnM.2019.34.3.247","article-title":"A\u00a0review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans","volume":"34","author":"Sargeant","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.clnu.2023.10.004_bib59","first-page":"2020","article-title":"Myopathy secondary to empagliflozin therapy in type 2 diabetes","author":"Gao","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.clnu.2023.10.004_bib60","doi-asserted-by":"crossref","first-page":"432","DOI":"10.7326\/L20-1456","article-title":"Rosuvastatin myotoxicity after starting canagliflozin treatment","volume":"174","author":"Brailovski","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clnu.2023.10.004_bib61","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1007\/s10072-022-06046-3","article-title":"A\u00a0case of anti-HMGCR myopathy triggered by sodium\/glucose co-transporter 2 (SGLT2) inhibitors","volume":"43","author":"Stella","year":"2022","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clnu.2023.10.004_bib62","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jdi.13137","article-title":"Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: a case report","volume":"11","author":"Yasuda","year":"2020","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.clnu.2023.10.004_bib63","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3389\/fendo.2020.00568","article-title":"Diabetes and sarcopenic obesity: pathogenesis, diagnosis, and treatments","volume":"11","author":"Wang","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnu.2023.10.004_bib64","first-page":"121","article-title":"Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization","volume":"7","author":"Xu","year":"2018","journal-title":"Adipocyte"},{"key":"10.1016\/j.clnu.2023.10.004_bib65","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/14740338.2015.1034105","article-title":"Short-term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events","volume":"14","author":"Yabe","year":"2015","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.clnu.2023.10.004_bib66","first-page":"1089","article-title":"Canagliflozin and renal outcomes in diabetic nephropathy","volume":"381","author":"Post","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clnu.2023.10.004_bib67","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2023.10.004_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis","volume":"63","author":"Wallenius","year":"2022","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.clnu.2023.10.004_bib69","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00100.2021","article-title":"Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies","volume":"322","author":"Takada","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.clnu.2023.10.004_bib70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clnu.2023.10.004_bib71","article-title":"Intramuscular adipose tissue, sarcopenia, and mobility function in older individuals","volume":"2012","author":"Marcus","year":"2012","journal-title":"J\u00a0Aging Res"},{"key":"10.1016\/j.clnu.2023.10.004_bib72","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"10.1016\/j.clnu.2023.10.004_bib73","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clnu.2023.10.004_bib74","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/dom.12923","article-title":"Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity","volume":"19","author":"Joannides","year":"2017","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2023.10.004_bib75","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.clnu.2023.10.004_bib76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1172\/JCI113570","article-title":"Effect of beta-hydroxybutyrate on whole-body leucine kinetics and fractional mixed skeletal muscle protein synthesis in humans","volume":"82","author":"Nair","year":"1988","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clnu.2023.10.004_bib77","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1113\/JP273185","article-title":"Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation","volume":"595","author":"Evans","year":"2017","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.clnu.2023.10.004_bib78","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fphys.2017.00310","article-title":"Intake of a ketone ester drink during recovery from exercise promotes mTORC1 signaling but not glycogen resynthesis in human muscle","volume":"8","author":"Vandoorne","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.clnu.2023.10.004_bib79","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ajcn\/nqy170","article-title":"Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies","volume":"108","author":"Thomsen","year":"2018","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2023.10.004_bib80","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/jcsm.12554","article-title":"Ketone bodies attenuate wasting in models of atrophy","volume":"11","author":"Koutnik","year":"2020","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2023.10.004_bib81","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.clnu.2023.10.004_bib82","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clnu.2023.10.004_bib83","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","article-title":"Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy","volume":"117","author":"Sandri","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.clnu.2023.10.004_bib84","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cmet.2007.11.001","article-title":"FoxO3 controls autophagy in skeletal muscle in\u00a0vivo","volume":"6","author":"Mammucari","year":"2007","journal-title":"Cell Metabol"},{"key":"10.1016\/j.clnu.2023.10.004_bib85","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13539-012-0074-6","article-title":"Molecular and cellular mechanisms of skeletal muscle atrophy: an update","volume":"3","author":"Fanzani","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2023.10.004_bib86","doi-asserted-by":"crossref","first-page":"E949","DOI":"10.1152\/ajpendo.00416.2015","article-title":"Mechanisms for greater insulin-stimulated glucose uptake in normal and insulin-resistant skeletal muscle after acute exercise","volume":"309","author":"Cartee","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.clnu.2023.10.004_bib87","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/dom.12237","article-title":"Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice","volume":"16","author":"Tatarkiewicz","year":"2014","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2023.10.004_bib88","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1038\/s41467-018-05439-3","article-title":"JNK regulates muscle remodeling via myostatin\/SMAD inhibition","volume":"9","author":"Lessard","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clnu.2023.10.004_bib89","doi-asserted-by":"crossref","first-page":"C190","DOI":"10.1152\/ajpcell.00066.2016","article-title":"Mitochondrial maintenance via autophagy contributes to functional skeletal muscle regeneration and remodeling","volume":"311","author":"Nichenko","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.clnu.2023.10.004_bib90","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1074\/jbc.275.4.2733","article-title":"Mitochondrial activity is involved in the regulation of myoblast differentiation through myogenin expression and activity of myogenic factors","volume":"275","author":"Rochard","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clnu.2023.10.004_bib91","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/15548627.2015.1115172","article-title":"Mitophagy is required for mitochondrial biogenesis and myogenic differentiation of C2C12 myoblasts","volume":"12","author":"Sin","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.clnu.2023.10.004_bib92","article-title":"Morphofunctional and Biochemical approaches for studying mitochondrial changes during myoblasts differentiation","volume":"2011","author":"Barbieri","year":"2011","journal-title":"J\u00a0Aging Res"},{"key":"10.1016\/j.clnu.2023.10.004_bib93","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48703-2","article-title":"Regulation of mitochondrial activity controls the duration of skeletal muscle regeneration in response to injury","volume":"9","author":"Pessemesse","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2023.10.004_bib94","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mito.2021.02.016","article-title":"Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications","volume":"58","author":"Afsar","year":"2021","journal-title":"Mitochondrion"},{"key":"10.1016\/j.clnu.2023.10.004_bib95","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00125-022-05851-x","article-title":"Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis","volume":"66","author":"Radlinger","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.clnu.2023.10.004_bib96","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.yexcr.2018.02.002","article-title":"Leucyl-tRNA synthetase is required for the myogenic differentiation of C2C12 myoblasts, but not for hypertrophy or metabolic alteration of myotubes","volume":"364","author":"Sato","year":"2018","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.clnu.2023.10.004_bib97","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1038\/s41401-022-00878-7","article-title":"Anti-diabetic drug canagliflozin hinders skeletal muscle regeneration in mice","volume":"43","author":"Lv","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.clnu.2023.10.004_bib98","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1152\/physrev.00031.2010","article-title":"Fiber types in mammalian skeletal muscles","volume":"91","author":"Schiaffino","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clnu.2023.10.004_bib99","doi-asserted-by":"crossref","first-page":"C629","DOI":"10.1152\/ajpcell.00368.2011","article-title":"Mitochondrial functional specialization in glycolytic and oxidative muscle fibers: tailoring the organelle for optimal function","volume":"302","author":"Picard","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.clnu.2023.10.004_bib100","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/j.2040-4603.2013.tb00534.x","article-title":"Mechanisms modulating skeletal muscle phenotype","volume":"3","author":"Blaauw","year":"2013","journal-title":"Compr Physiol"},{"key":"10.1016\/j.clnu.2023.10.004_bib101","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2337\/db11-1299","article-title":"A\u00a0novel method to measure glucose uptake and myosin heavy chain isoform expression of single fibers from rat skeletal muscle","volume":"61","author":"Mackrell","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.clnu.2023.10.004_bib102","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2337\/db14-0590","article-title":"Human muscle fiber type-specific insulin signaling: impact of obesity and type 2 diabetes","volume":"64","author":"Albers","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.clnu.2023.10.004_bib103","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2012-3876","article-title":"Slow-twitch fiber proportion in skeletal muscle correlates with insulin responsiveness","volume":"98","author":"Stuart","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clnu.2023.10.004_bib104","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0022-510X(73)90023-3","article-title":"Data on the distribution of fibre types in thirty-six human muscles. An autopsy study","volume":"18","author":"Johnson","year":"1973","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.clnu.2023.10.004_bib105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1573399810666140918121022","article-title":"Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II","volume":"10","author":"Cetrone","year":"2014","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.clnu.2023.10.004_bib106","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s10495-006-0194-6","article-title":"Death receptor-associated pro-apoptotic signaling in aged skeletal muscle","volume":"11","author":"Pistilli","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.clnu.2023.10.004_bib107","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2169\/internalmedicine.7134-21","article-title":"Effects of canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"60","author":"Nishimiya","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.clnu.2023.10.004_bib108","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clnu.2023.10.004_bib109","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bbadis.2008.10.011","article-title":"The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy","volume":"1782","author":"Murton","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clnu.2023.10.004_bib110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00424-010-0919-9","article-title":"The role and regulation of MAFbx\/atrogin-1 and MuRF1 in skeletal muscle atrophy","volume":"461","author":"Foletta","year":"2011","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.clnu.2023.10.004_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients Irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clnu.2023.10.004_bib112","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.diabres.2017.11.016","article-title":"Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment","volume":"135","author":"Horie","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clnu.2023.10.004_bib113","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy balance after sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clnu.2023.10.004_bib114","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1681\/ASN.2016050510","article-title":"Dapagliflozin Binds specifically to sodium-glucose cotransporter 2 in the proximal renal Tubule","volume":"28","author":"Ghezzi","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.clnu.2023.10.004_bib115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clnu.2023.10.004_bib116","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jcsm.12268","article-title":"Pitfalls in the measurement of muscle mass: a need for a reference standard","volume":"9","author":"Buckinx","year":"2018","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2023.10.004_bib117","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1210\/jc.2008-2216","article-title":"Changes in basal and insulin and amino acid response of whole body and skeletal muscle proteins in obese men","volume":"94","author":"Guillet","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.clnu.2023.10.004_bib118","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/BJ20120772","article-title":"A\u00a0novel PKB\/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle","volume":"447","author":"Lai","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.clnu.2023.10.004_bib119","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/14656566.2022.2113385","article-title":"Dual sodium-glucose cotransporter (SGLT) 1\/2 versus pure SGLT2 inhibitors: two distinct drug categories or one class with multiple faces?","volume":"23","author":"Koufakis","year":"2022","journal-title":"Expet Opin Pharmacother"},{"key":"10.1016\/j.clnu.2023.10.004_bib120","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40266-023-01042-4","article-title":"Repurposing drugs for diabetes mellitus as potential pharmacological treatments for sarcopenia - a narrative review","volume":"40","author":"Witham","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clnu.2023.10.004_bib121","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/17512433.2023.2247977","article-title":"Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?","volume":"16","author":"Koufakis","year":"2023","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.clnu.2023.10.004_bib122","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/M21-4776","article-title":"Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction : a post hoc analysis of the DAPA-HF trial","volume":"175","author":"Butt","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clnu.2023.10.004_bib123","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","article-title":"SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: Insights from frail hypertensive and diabetic patients","volume":"79","author":"Mone","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.clnu.2023.10.004_bib124","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2023.0035","article-title":"Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity","author":"Kim","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clnu.2023.10.004_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155664","article-title":"From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","volume":"147","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.clnu.2023.10.004_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/nu15040891","article-title":"Impact of sarcopenia on non-alcoholic fatty liver disease","volume":"15","author":"Iwaki","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2023.10.004_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.07.009","article-title":"Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: ex quo et quo vadimus?","volume":"98","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.clnu.2023.10.004_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: an updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J\u00a0Diabet Complicat"},{"key":"10.1016\/j.clnu.2023.10.004_bib129","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnu.2023.10.004_bib130","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2337\/diacare.25.12.2335","article-title":"A\u00a0randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes","volume":"25","author":"Castaneda","year":"2002","journal-title":"Diabetes Care"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561423003229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561423003229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T01:14:00Z","timestamp":1759367640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561423003229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":130,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0261561423003229"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2023.10.004","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A\u00a0controversy that must be solved","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2023.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.","name":"copyright","label":"Copyright"}]}}